EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights

Md Takdir Hossain iD, Md Arafat Hossain iD

Drug Development Research · 2025-11 · 86 (7)

DOI: 10.1002/ddr.70167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 05.10.2025. Verfasst von Md Takdir Hossain und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh. Hauptthemen laut MEDLINE: Neoplasms, TOR Serine-Threonine Kinases, MTOR Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 372 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a significant global health challenge, with increasing incidence and mortality rates worldwide. The mechanistic target of rapamycin (mTOR) pathway, a central regulator of cell growth, proliferation, metabolism, and survival, has emerged as a promising therapeutic target in cancer. Dysregulation of mTOR signaling is implicated in various cancers, including breast, colon, lung, renal cell carcinoma, and multiple myeloma, making it an attractive target for inhibition. This review provides a comprehensive analysis of mTOR‐targeted therapies, focusing on the clinical outcomes, efficacy, safety, and adverse effects of mTOR inhibitors. We explore the mechanisms of mTOR regulation, the impact of mTOR mutations on drug sensitivity, and the development of resistance to mTOR inhibitors. The review also highlights the potential of combination therapies and next‐generation inhibitors to overcome resistance and improve therapeutic outcomes. Key mTOR inhibitors, including rapalogs (e.g., sirolimus, everolimus) and ATP‐competitive inhibitors (e.g., MLN0128, PP242), are discussed in detail, along with their clinical applications and limitations. Additionally, we summarize the findings from major clinical trials, including FDA‐approved mTOR inhibitors like everolimus and temsirolimus, and non‐FDA‐approved inhibitors such as sapanisertib and ridaforolimus. The review underscores the importance of understanding mTOR signaling and its role in cancer progression, offering insights into the future of mTOR‐targeted therapies in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTOR Serine-Threonine KinasesMTOR InhibitorsAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimalsMolecular Targeted TherapySignal TransductionDrug Resistance, Neoplasm

Stichwörter der Autor:innen

clinical trialsmTOR inhibitorsmTOR signaling pathwaytargeted therapytherapeutic resistance

Substanzen

TOR Serine-Threonine KinasesMTOR InhibitorsMTOR protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh.

ORCID-Profile: Md Takdir Hossain, Md Arafat Hossain

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Hossain, M. T., & Hossain, M. A. (2025). Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights. Drug Development Research, 86(7). https://doi.org/10.1002/ddr.70167

Vancouver

Hossain MT, Hossain MA. Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights. Drug Development Research. 2025;86(7). doi:10.1002/ddr.70167

BibTeX
@article{Hossain2025,
  author = {Hossain, Md Takdir and Hossain, Md Arafat},
  title = {Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights},
  journal = {Drug Development Research},
  year = {2025},
  volume = {86},
  number = {7},
  doi = {10.1002/ddr.70167}
}
Kostenlos starten →